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Abstract
A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneu-
monia after treatment with paclitaxel. The patient had acute chills and fever on the fourth day
after the second exposure to paclitaxel, rapidly got worse despite empiric therapies, and developed
prolonged respiratory failure requiring mechanical ventilation. Four months later, he died of res-
piratory failure due to progression of both interstitial pneumonia and lung cancer. This is the first
case developing fatal paclitaxel-induced pulmonary toxicity to date. Interstitial pneumonia should
be considered one of the possible life-threatening complications during treatment with paclitaxel.
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A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after 
treatment with paclitaxel.  The patient had acute chills and fever on the fourth day after the second 
exposure to paclitaxel,  rapidly got worse despite empiric therapies,  and developed prolonged respira-
tory failure requiring mechanical ventilation.  Four months later,  he died of respiratory failure due 
to progression of both interstitial pneumonia and lung cancer.  This is the ﬁ rst case developing fatal 
paclitaxel-induced pulmonary toxicity to date.  Interstitial pneumonia should be considered one of the 
possible life-threatening complications during treatment with paclitaxel.
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aclitaxel (Taxol,  Bristol-Myers-Squibb, 
Princeton,  NJ,  USA) is a taxane anti-neoplas-
tic agent with a broad spectrum of activity for vari-
ous cancers.  Major adverse eﬀ ects are peripheral 
neuropathy,  myelotoxicity,  bradycardia,  hypoten-
sion,  arthralgia,  myalgia,  granulocytopenia and 
hypersensitivity [1,  2].  Hypersensitivity reactions 
are well-recognized complications of paclitaxel 
administration and typically occur during the ﬁ rst or 
second exposure [3,  4].  These reactions,  consisting 
of dyspnea with or without bronchospasms,  urticaria, 
rashes,  hypotension,  or angioedema,  have been 
thought to be attributable to both paclitaxel itself 
and to its diluent,  Cremophor EL.  Because of the 
high incidence of hypersensitivity reactions,  a stan-
dardized premedication regimen using high-dose 
dexamethasone,  diphenhydramine,  and cimetidine is 
prescribed for prophylaxis of paclitaxel-induced 
hypersensitivity reactions in Japan.
　　Although several cases developing paclitaxel-
induced interstitial pneumonia have been reported to 
date [5],  they have generally responded to cortico-
steroid treatment.  A fatal case of paclitaxel-induced 
interstitial pneumonia has not been reported in the 
literature to date.  We describe here a patient with 
advanced adenocarcinoma of the lung developing 
acute life-threatening interstitial pneumonia on the 
fourth day after the second exposure to paclitaxel, 
and review the previous reports of interstitial pneu-
monia induced by paclitaxel.
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Case Report
　　A 71-year-old Japanese man was diagnosed with 
adenocarcinoma of the lung by the cytological exami-
nation of pleural eﬀ usion at a local clinic and 
referred to our hospital.  He had a 40-pack-a-year 
history of cigarette smoking and no history of pulmo-
nary disease.  He had been a clerical staﬀ  member at 
city hall,  and he had no allergic history.
　　Physical examination on admission revealed a 
weakness of breath sounds in the right lung. 
Laboratory ﬁ ndings showed an elevated white blood 
cell (WBC) count (9,000/mm3),  serum levels of 
C-reactive protein (CRP : 7.3 mg/dl),  carcinoembry-
onic antigen (CEA : 29.76 ng/ml),  progastrin releas-
ing peptide (pro-GRP : 38.3 pg/ml),  sialyl Lewis-X-I 
antigen (SLX : 54.1 U/ml),  and neuron-speciﬁ c eno-
lase (NSE : 18.70 ng/ml).  Arterial blood gas analysis 
revealed that the pH was 7.42,  PaO2 77.3 mmHg, 
and PaCO2 40.0 mmHg.  Computed tomography (CT) 
scans of the chest revealed a nodule on the right S3b, 
mediastinal lymph node swelling,  and right pleural 
eﬀ usion without interstitial lung disease.  Pulmonary 
function data were as follows : 1-second forced expi-
ratory volume,  79.4ｵ ; vital capacity,  47.9ｵ ; car-
bon monoxide diﬀ using capacity,  12.5 mL/min/mmHg 
(78.9ｵ).  After completion of the staging work-ups, 
the clinical stage was determined to be T4N2M1 (stage 
IV).  Systemic chemotherapy consisting of paclitaxel 
80 mg/m2 (130 mg/body) by 1-hour intravenous infu-
sion given on days 1 and 8 was started.  He was given 
premedication consisting of dexamethasone (16 mg), 
diphenhydramine (50 mg),  and ranitidine (50 mg).
　　On day 12,  he felt feverish and had chills.  His 
temperature was 37.9 °C,  pulse 75/min,  blood pres-
sure 138/80 mmHg,  respiratory rate 25/mim,  and 
oxygen saturation (SaO2) 90ｵ with room air. 
Arterial blood gas analysis showed that pH was 7.46, 
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Fig. 1　　A,  Chest radiograph shows diﬀ use shadows in the left middle and lower lung ﬁ elds ; B,  CT scans of the chest demonstrate 
ground-glass opacities ; C,  D : Chest radiograph and CT scans of the chest showed extensive areas of ground-glass opacities and 
traction bronchiectasis.  The distribution was predominantly in the lower zone.
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PaO2 63.5 mmHg,  and PaCO2 34.4 mmHg.  Mild ﬁ ne 
crackles were audible in the left lung.  The WBC 
count was 3,300/mm3,  including 70.0ｵ neutrophils 
and 22.0ｵ lymphocytes.  Serum levels of CRP,  lac-
tate dehydrogenase,  and KL-6 were 15.0 mg/dl, 
704 U/l,  and 1,139 U/ml,  respectively.  Culture of 
the sputum and peripheral blood detected no patho-
genic organisms.  Serological tests for candida, 
mycoplasma,  pneumocystis jiroveci,  and cytomegalo-
virus were negative.  The chest radiograph showed 
diﬀ use shadows in the left middle and lower lung 
ﬁ elds (Fig.  1A).  CT scans of the chest demonstrated 
ground-glass opacities (Fig.  1B).  We therefore 
determined that he had paclitaxel-induced interstitial 
pneumonia.
　　He was immediately treated with steroid pulse 
therapy (methylprednisolone,  1 g/day for 3 days). 
Five days later,  since his symptoms and the intersti-
tial shadows on the chest radiograph did not improve, 
he received the second cycle of steroid pulse therapy 
(methylprednisolone,  2 g/day for 3 days).  Further-
more,  he was given cyclophosphamide (750 mg/day) 
on day 31 from the initiation of chemotherapy (10 
days after the last pulse therapy),  but his general 
condition did not improve.  CT scans of the chest 
showed extensive areas of ground-glass opacities with 
interlobular septal thickening and traction bronchiec-
tasis,  and the distribution was predominantly in the 
lower zone (Fig.  1 C,  D).  He was then intubated 
with mechanical ventilatory support the next day.  On 
day 128 from the initiation of chemotherapy,  he died 
of respiratory failure due to progression of intersti-
tial pneumonia and lung cancer.  Autopsy was not 
allowed.
Discussion
　　Drug-induced interstitial pneumonia is a rare com-
plication of paclitaxel administration.  There have 
been a few reports of paclitaxel-induced interstitial 
pneumonia to date.  Furuse et al. have reported that 
the incidence of interstitial pneumonia in patients 
with previously untreated advanced NSCLC is 
approximately 3ｵ in phase II [1],  but that it 
increases to approximately 50ｵ in patients with 
locally advanced NSCLC receiving concurrent radio-
therapy [6].  Although premedication for paclitaxel 
administration is commonly carried out for prophy-
laxis of hypersensitivity reactions,  the true eﬃ  cacy 
is still unconﬁ rmed because severe hypersensitivity 
reactions have been reported despite premedication, 
just as we experienced in this case.  Docetaxel and 
paclitaxel have similar mechanisms of action as 
microtubule-stabilizing drugs and have similar 
adverse eﬀ ects of interstitial pneumonia.  Although 
there have been several reports of severe interstitial 
pneumonia by docetaxel [7,  8],  this is the ﬁ rst 
known case to developing fatal paclitaxel-induced pul-
monary toxicity.  Interstitial pneumonia induced by 
geﬁ tinib and leﬂ unomide tends to occur in Japanese 
more frequently than in Westerners [9,  10].  To our 
best knowledge,  interstitial pneumonia has not been 
reported in Western phase II studies of paclitaxel 
monotherapy,  although there have been a few case 
reports [4,  5,  11].  Two Japanese phase II studies, 
reported by Furuse et al. and Sekine et al.,  have 
shown the frequency of interstitial pneumonia to be 3
ｵ and 1.7ｵ,  respectively [1,  2].  As such,  there 
may be ethnic diﬀ erences in the frequency of inter-
stitial pneumonia by paclitaxel.
　　The mechanism of drug-induced interstitial pneu-
monia is not well understood.  Most researchers 
agree that it is the consequence of a cell-mediated 
immunologic reaction.  Drug-induced interstitial pneu-
monia is diagnosed by a drug lymphocyte stimulation 
test (DLST) coupled with bronchoalveolar lavage or 
transbronchial lung biopsy ﬁ ndings.  However,  these 
examinations could not be performed in the present 
case due to severe respiratory failure caused by life-
threatening pneumonia.  DLST using peripheral 
blood is also useful as an in vitro method of screening 
for drug allergy.  It should have been performed in 
this patient,  although the positive ratio was reported 
to be only 33ｵ [12] and a positive result does not 
indicate the drug responsible for the symptoms,  only 
a sensitization to that drug [13].  In the present 
case,  paclitaxel-induced pneumonia was diagnosed by 
excluding the other possible etiologies and consider-
ing the clinical course.
　　The ﬁ rst treatment for paclitaxel-induced intersti-
tial pneumonia is the withdrawal of this drug.  Some 
patients developing paclitaxel-induced pneumonia 
improve spontaneously [11].  The second choice of 
treatment is administration of corticosteroid.  Usually 
prednisolone at a dose of 30 to 60 mg per day is 
given for 2 to 3 weeks,  and higher doses like pulse 
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therapy are administered for more severe conditions 
such as acute respiratory failure,  with a slow and 
careful tapering-oﬀ  period.  Because paclitaxel-
induced interstitial pneumonia usually responds rap-
idly to steroid therapy [5,  11],  steroid-refractory 
cases have not been reported.  Although this patient 
had no history of pulmonary disease or thoracic radi-
ation therapy,  he responded to neither an immuno-
suppressive agent nor steroid pulse therapy.  In sev-
eral cases,  predominant CT ﬁ ndings showed ground-
glass opacities and interlobular septal thickening [14]. 
The CT images of drug-induced pneumonia are usu-
ally classiﬁ ed into interstitial pneumonia/ﬁ brosis, 
diﬀ use alveolar damage,  organizing pneumonia reac-
tion,  or a hypersensitivity reaction [15].  Ichikado et 
al. have reported that patients with acute interstitial 
pneumonia who have CT ﬁ ndings suggestive of the 
ﬁ broproliferative phase of diﬀ use alveolar damage, 
particularly ﬁ ndings of architectural distortion,  and 
ground-glass attenuation associated with traction 
bronchiectasis,  have a worse prognosis than patients 
without these ﬁ ndings [16].  In the present case,  CT 
ﬁ ndings showed ground-glass opacities and traction 
bronchiectasis,  which were compatible with acute 
lung injury characterized pathologically by diﬀ use 
alveolar damage [17].  If CT ﬁ ndings in paclitaxel-
induced pneumonia show traction bronchiectasis dur-
ing the acute phase,  the prognosis may be worse.
　　In conclusion,  we have reported herein a case 
with advanced lung cancer developing paclitaxel-
induced,  acute life-threatening interstitial pneumonia. 
Although this complication rarely occurs,  physicians 
should be alert to this unusual and possibly life-
threatening adverse eﬀ ect of paclitaxel,  in order to 
begin treatment as soon as possible.
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